In Foundayo's ATTAIN-1 trial, participants at the highest approved dose (17.2mg) lost an average of 11.1% of their body weight over 72 weeks, compared with 2.1% on placebo. Results build gradually: early changes in appetite are often noticed within the first few weeks, but the most significant weight loss builds over months, particularly once an effective dose is reached, since Foundayo's titration schedule takes a minimum of five months to reach the maximum dose. Around 18.4% of participants at the highest dose achieved 20% or more total weight loss. Individual results vary considerably, and consistent use alongside diet and lifestyle changes plays a significant role in your own outcome.
Most before-and-after content for established medicines like Mounjaro and Wegovy draws on years of accumulated real-world patient experiences, alongside trial data. Foundayo doesn't have that history yet — it's a genuinely new medicine in the UK. What it does have is a robust clinical trial programme (ATTAIN) involving thousands of participants, tracked carefully over 72 weeks, which gives a realistic and evidence-based picture of what results actually look like over time, even without individual UK patient photos to point to yet.
What the Trial Data Shows, Stage by StageThe First Few Weeks (Titration Begins)
Foundayo starts at a low 0.8mg dose, specifically designed to ease your body into treatment rather than produce significant weight loss immediately. Many people notice early appetite changes during this period — a quieting of "food noise" and feeling fuller sooner — but visible weight change is typically modest at this stage, and that's expected, not a sign anything is wrong. Patience during these early weeks matters more than it might feel like at the time.
The Middle Titration Period (Months 2–5)
As the dose gradually increases through the titration schedule, appetite suppression tends to become more noticeable, and this is where most people start to see steady, visible progress. Side effects, if they occur, are also most likely during this window, particularly around dose increases — see our dedicated Foundayo side effects guide for what to expect and how to manage this period.
Reaching an Effective Dose (Around 5 Months Onward)
Once you reach a dose that's working well for you — which isn't necessarily the maximum 17.2mg for everyone — results tend to build more consistently. See our dedicated Foundayo dosage and titration guide for the complete schedule. In the ATTAIN-1 trial, the most significant average results were seen by 72 weeks, reflecting sustained treatment at an effective dose over many months, not a quick transformation.
Beyond 72 Weeks
The ATTAIN-1 trial measured results at 72 weeks, and continuing treatment beyond this point, alongside sustained diet and lifestyle habits, is how results are maintained over the longer term. Weight regain is a recognised risk if treatment stops or lifestyle habits aren't sustained — this is consistent with the pattern seen across the GLP-1 medicine class generally, not specific to Foundayo.
| Outcome | Percentage of participants (highest dose) |
|---|---|
| Achieved 5% or more weight loss | Majority of participants |
| Achieved 10% or more weight loss | Substantial proportion |
| Achieved 20% or more weight loss | 18.4% |
| Placebo group average | 2.1% |
It's genuinely useful to know what that percentage translates to physically. For someone starting at 100kg, an 11.1% average weight loss represents around 11kg lost over 72 weeks of consistent treatment — a substantial and clinically meaningful change, even though it's more modest than some other currently available options.
Worth knowing
The 11.1% average figure is exactly that — an average across a large trial population. Averages describe the typical result, not a guarantee for any individual. Some people in the trial achieved considerably more than 11.1%, others less, which is exactly why realistic expectations matter more than fixating on a single headline number.
Trial data on Foundayo also captured changes beyond body weight alone, including waist circumference and markers linked to metabolic health. For many people, non-scale changes — how clothes fit, energy levels, or improvements in blood pressure and blood sugar markers where relevant — become just as meaningful as the headline weight-loss percentage over time. If you're tracking your own progress, it's worth paying attention to these broader indicators alongside the number on the scale, rather than focusing on weight alone.
- Consistency with your titration schedule — reaching and staying at an effective dose matters more than rushing through it
- Diet and lifestyle changes alongside treatment, since Foundayo is licensed to work in combination with a reduced-calorie diet and increased physical activity, not as a standalone solution
- How well you tolerate and manage side effects, since discomfort that leads to skipped doses or early discontinuation limits how much benefit you see
- Your starting weight and individual biology, which affect both the pace and total scale of weight loss achievable for you specifically
- Whether you're using Foundayo for weight management specifically, or as part of managing type 2 diabetes, since the evidence base and expected outcomes differ between these two licensed uses
- How you handle any side effects during titration, since managing discomfort well tends to support staying consistent with treatment over the months needed to see full results
It's worth being honest that Foundayo's average trial results are somewhat more modest than Mounjaro's (up to 22.5% at 72 weeks) or the Wegovy pill's (up to 20.7% assuming full adherence), based on current trial data — see our dedicated Foundayo vs Mounjaro guide and Foundayo vs Wegovy Pill guide for more detail on how the options differ. This doesn't mean Foundayo won't work well for you specifically, but it's a genuine, honest data point worth knowing rather than assuming otherwise. For many people, Foundayo's tablet format and lack of any fasting requirement are the deciding factors, independent of which medicine shows the highest average number in a trial.
Important
Never judge your own progress purely against trial averages, and never increase your dose independently in an attempt to accelerate results. Titration schedules exist for safety reasons, and your prescriber is the right person to discuss your individual progress with, particularly if results feel slower than you expected.
As more people in the UK start Foundayo and share their experiences, real-world data will begin to complement the clinical trial evidence — this is a normal pattern seen with every new medicine. Real-world results sometimes differ slightly from trial averages, since trial participants follow a structured protocol with close monitoring, while everyday use involves more individual variation in consistency, diet and lifestyle. Over the coming months and years, this real-world picture will likely become an increasingly useful complement to the ATTAIN trial data covered in this guide, and we'll continue to update our content as that picture develops.
See What Foundayo® Could Do For You
Foundayo® is available to order now through Happy Pharmacy. A free online consultation with our GPhC-registered pharmacy team can help you understand what realistic results might look like for your specific circumstances.
Start Your Free Online Consultation → Happy Pharmacy is a GPhC-registered pharmacy (No. 9012585) — Superintendent Pharmacist: Palvinder Deol — Rated 4.8★ Excellent on Trustpilot- Wharton S, et al. ATTAIN-1. N Engl J Med, September 2025.
- Foundayo® (orforglipron) Summary of Product Characteristics, MHRA Products website.
- MHRA. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes, 10 August 2026.
- Eli Lilly and Company. Foundayo™ (orforglipron) Medication Guide, lilly.com.
- NICE. Technology appraisal guidance for orforglipron, weight management and type 2 diabetes.